Referred to the House Committee on Energy and Commerce.
The Stop CMV Act of 2025 would add a new section to the Public Health Service Act authorizing hospitals and other health care entities to administer testing for congenital Cytomegalovirus (CMV) to infants 21 days old or younger. It directs State chief health officers to set standards for testing, recordkeeping, follow-up, and information dissemination; if a State fails to do so within two years, the federal Advisory Committee on Heritable Disorders in Newborns and Children would set standards.
Scope and source of authority: liberals/centrists view federal technical support and Advisory Committee oversight as evidence-based assistance; conservatives see the Advisory Committee fallback as potential federal overreach.
Relative to its intended legislative type, this bill establishes a substantive change by creating a statutory framework for congenital CMV screening of newborns, assigns roles to States and existing federal entities, and authorizes limited federal funding and research activities.
The Stop CMV Act of 2025 would add a new section to the Public Health Service Act authorizing hospitals and other health care entities to administer testing for congenital Cytomegalovirus (CMV) to infants 21 days old or younger.
It directs State chief health officers to set standards for testing, recordkeeping, follow-up, and information dissemination; if a State fails to do so within two years, the federal Advisory Committee on Heritable Disorders in Newborns and Children would set standards.
The bill authorizes HRSA grants to States to fund testing, CDC grants or cooperative agreements for technical assistance, data systems, and education, and directs NIH to establish or expand research programs on screening, diagnostics, prevention, treatments, vaccines, and related public health awareness.
Content-wise the bill is a narrowly targeted public‑health measure with low ideological salience and built‑in deference to States, which historically increases the chance of enactment. The presence of new, though undefined, spending and cross‑agency implementation raises some fiscal and procedural questions that could slow or modify passage, but the topic's noncontroversial nature and grant‑based approach make enactment plausible if legislative time and appropriations priorities allow.
Relative to its intended legislative type, this bill establishes a substantive change by creating a statutory framework for congenital CMV screening of newborns, assigns roles to States and existing federal entities, and authorizes limited federal funding and research activities. The construction is moderately specific where it designates responsible actors and a two‑year fallback mechanism, but it leaves many operational and programmatic details to implementing authorities.
Scope and source of authority: liberals/centrists view federal technical support and Advisory Committee oversight as evidence-based assistance; conservatives see the Advisory Committee fallback as potential federal overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and source of authority: liberals/centrists view federal technical support and Advisory Committee oversight as evidence-based assistance; conservatives see the Advisory Committee fallback as potential federal over…
This persona would generally view the bill positively as a public-health measure that expands newborn screening and funds research and education to reduce CMV-related disability.
They would note the bill's provisions for state standards, CDC technical assistance, and NIH research as strengths that can improve early detection and treatment access.
They would be attentive to equity and access concerns, seeking to ensure that follow-up care and coverage are available for low-income and marginalized families.
A centrist would likely support the bill's public-health intent and the emphasis on evidence-based standards, CDC technical assistance, and NIH research, while remaining cautious about costs and implementation clarity.
They would appreciate the state-led approach and the Advisory Committee's role as a technical backstop, but want clear timelines, accountability, and realistic funding plans.
They would be concerned that authorization language and the short authorized funding window leave uncertainty about sustainability and state-level burdens.
This persona would be cautious or skeptical about the bill because it expands federal involvement in newborn screening and creates potential fiscal and regulatory obligations for states and hospitals.
They would view the fallback provision allowing the Advisory Committee to impose standards after two years as a federal encroachment on state authority.
Concerns would include open-ended funding language, parental choice and consent not being explicit, data collection/privacy, and expansion of NIH programs.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content-wise the bill is a narrowly targeted public‑health measure with low ideological salience and built‑in deference to States, which historically increases the chance of enactment. The presence of new, though undefined, spending and cross‑agency implementation raises some fiscal and procedural questions that could slow or modify passage, but the topic's noncontroversial nature and grant‑based approach make enactment plausible if legislative time and appropriations priorities allow.
The bill has not accumulated any surfaced votes yet.
Scope and source of authority: liberals/centrists view federal technical support and Advisory Committee oversight as evidence-based assista…
Content-wise the bill is a narrowly targeted public‑health measure with low ideological salience and built‑in deference to States, which hi…
Relative to its intended legislative type, this bill establishes a substantive change by creating a statutory framework for congenital CMV screening of newborns, assigns roles to States and existing federal entities, an…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.